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Abstract The STAT multigene family of transcriptional
regulators conveys signals from several cytokines and growth
factors upon phosphorylation by janus kinases (JAK). Activation
of STAT5 is typically mediated by JAK2, but more recent data
indicate a direct activation by the insulin receptor kinase. STAT5
exists in two closely homologous isoforms, STAT5a and b. We
here describe the selective tyrosine phosphorylation of STAT5b
in Kym-1 cells in response to insulin. Blocking insulin signalling
by HNMPA-(AM)3, an insulin receptor kinase inhibitor,
resulted in the loss of insulin-induced STAT5b tyrosine
phosphorylation, whereas the inhibition of JAK2 by the JAK
selective inhibitor tyrphostin AG490 had no effect. By contrast,
in the same cells, IFNQ-induced STAT5b activation was JAK2-
dependent, indicating that this signal pathway is functional in
Kym-1 cells. We conclude from this rhabdomyosarcoma model
that STAT5b, but not STAT5a is a direct target of the insulin
receptor kinase.
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1. Introduction
Signal transducer and activator of transcription 5 (STAT5)
belongs to the family of STAT e¡ector molecules [1,2] down-
stream of cellular receptors leading to the induction of target
genes upon activation by interferons, a wide range of cyto-
kines including prolactin (PRL), erythropoietin, thrombopoie-
tin, granulocyte macrophage colony stimulating factor (GM-
CSF), interleukin (IL)-2, IL-3, IL-5, IL-7, IL-9 and growth
hormone (GH) [3^8]. STAT transcription factors play impor-
tant roles in many cell types and mediate several responses,
e.g. proliferation, cell cycle control, cell di¡erentiation [7,9^12]
and prevention of apoptosis [13,14]. The physiologic function
of STAT5 is not yet fully elucidated [3,4]. Evidence for a
multifunctional role stems from the observation that STAT5
is capable to act in concert with other transcription factors
too, e.g. with the glucocorticoid receptor [9].
Recently, beside insulin receptor substrate (IRS), STAT5
has been described as an additional, direct substrate of the
insulin receptor [15,16], and has been implicated to participate
in the regulation of the transcriptional program of insulin
responsive genes in myotubes [17]. STAT5 interacts with
IRL in the two hybrid system, gets tyrosine phosphorylated
by puri¢ed IR kinase domain in vitro [15], and a direct inter-
action between these two signalling proteins was demon-
strated by docking of STAT5 via src homology (SH)2-do-
mains to Y960 of the insulin receptor L-chain [16]. Two
STAT5 homologues, STAT5a and STAT5b, which share
96% amino acid sequence identity are known so far [18,19].
Though both STAT5 isoforms are simultaneously activated
by a number of cytokines, it is not clari¢ed yet, if one or
both STAT5 isoforms are activated by insulin, and if activa-
tion via JAK2 plays a role in insulin-mediated STAT activa-
tion. While cytokine i.e. GH and PRL-induced activation of
STAT5 is mediated by the janus kinase (JAK)2, [3,20^22], in
insulin signalling, JAK2-dependent and independent STAT5
activation was reported [3,23^26]. We here demonstrate in
Kym-1 rhabdomyosarcoma cells that insulin-induced STAT
activation is restricted to the STAT5b isoform. Furthermore
this activation is, in contrast to interferon (IFN)Q-induced
STAT5b activation in the same cells, independent of JAK2
activation and a direct consequence of binding to and phos-
phorylation by IRL kinase.
2. Materials and methods
2.1. Cell culture and transfection
The human rhabdomyosarcoma cell line Kym-1 was cultured in
Clicks RPMI 1640 medium supplemented with 10% FCS. Kym-1 cells
were grown to 80% con£uence in tissue culture plates. Before treat-
ment with IFNQ or insulin, Kym-1 cells were serum starved (clicks
RPMI 1640, without (w/o) FCS) for 2 h and stimulated as indicated
for various concentrations and times. Rat1 ¢broblasts overexpressing
the human insulin receptor (Rat1 HIR cl5) were a kind gift of A.
Ullrich, Max Planck Institut fu«r Biochemie, 82152 Martinsried, Ger-
many. Rat1 HIR cl5 cells were cultured in DMEM (4.5 g/l glucose)
medium supplemented with 10% FCS. Transfection of these cells was
performed by lipofection (Pfx-6), using the Pfx-kit (Invitrogen) under
standard conditions.
2.2. Cytokines, antibodies and reagents
Insulin from bovine pancreas was purchased from Sigma, and IFNQ
was a kind gift of B. Otto, Fraunhofer Institut fu«r Grenz£a«chen und
Bioverfahrenstechnik, Hannover, Germany. Antibodies against insu-
lin receptor L (C-19), STAT5a (L-20, selective for STAT5a), STAT5b
(G-2, selective for STAT5b), STAT5 (C-17) and JAK2 (HR-758) were
from Santa Cruz. The phosphotyrosine antibody 4G10 was from Up-
state. All inhibitors of proteases and phosphatases were from Biomol.
Secondary alkaline phosphatase (AP)-linked antibodies, goat anti-
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mouse IgG and IgM (H+L), and goat anti-rabbit IgG (H+L) were
from Dianova. The STAT5b expression vector (pXM-mSTAT5b) was
a kind gift of B. Groner, Georg-Speyer-Haus, Frankfurt/M, Germany
[9]. The insulin receptor inhibitor HNMPA-(AM)3 (hydroxy-2-naph-
talenylmethylphosphonic acid Tris acetoxymethylester) was from Cal-
biochem, and the JAK2 inhibitor tyrphostin AG490 (tyrphostin B42)
was from Alexis Corporation.
2.3. Cell lysis and immunoprecipitation
After stimulation the cells were washed three times with PBS (4‡C)
and scraped in 750 Wl ice-cold lysisbu¡er (50 mM Tris^HCl pH 7.4,
1% Triton X-100 (v/v), 150 mM NaCl, 5 mM EDTA pH 7.4, 1 mM
NaF, 1 mM NaPP, 2 mM sodium orthovanadate, 1 mM sodium
molybdate, 100 nM okadaic acid, 100 nM calyculin A, 1 mM p-nitro-
phenyl-phosphate, 1 Wg/ml leupeptin, 1 Wg/ml aprotinin, 1 mM
PMSF). After 1 h cell lysis, the lysates were centrifuged (10 000Ug,
15 min, 4‡C) and immunoprecipitation (1 Wg/ml antibody or antise-
rum per sample) was performed as described [17]. Protein contents in
lysates were determined with the Bio-Rad Protein Assay using BSA as
a standard.
2.4. JAK2 kinase assay
The cells were lysed as described above. After immunoprecipitation
of JAK2, the Protein-A pellets were washed thrice (50 mM Tris^HCl
pH 7.4, 150 mM NaCl) and re-suspended in 30 Wl of kinase bu¡er (20
mM Tris^HCl pH 7.4, 50 mM NaCl, 10 mM MgCl2). After addition
of 4 WCi Q-[32P]ATP (Amersham) in 10 Wl kinase bu¡er, the samples
were incubated for 15 min at 37‡C. The reaction was stopped by
addition of 2Ureducing Laemmli bu¡er, the samples were separated
on 7.5% SDS^PAGE, and blotted on nitrocellulose. Quantitative
analysis of the kinase assays was performed with a phosphoimager
(Molecular Dynamics).
3. Results
3.1. Functionality of the insulin receptor signalling, and direct
association of STAT5 and IRL
To demonstrate the functionality of the insulin receptor
cascade, the tyrosine phosphorylations of the insulin receptor
L-chain (IRL), and one of its substrates, IRS-1, were analyzed.
Treatment of Kym-1 cells with insulin for 5 min resulted in an
induction of IRL tyrosine phosphorylation (Fig. 1a, left panel)
and increase in IRS-1 tyrosine phosphorylation (Fig. 1a, right
panel), whereas insulin had no e¡ect on protein levels. Of
note, IRS-1 shows in these cells a low, but clearly discernible
basal phosphorylation. As no basal IRL activity was detect-
able, this could re£ect activation of IRS by other endogenous
signals constitutively present in these transformed cells. Direct
association between the insulin receptor L-chain and STAT5
could be veri¢ed by co-immunoprecipitation analysis using
STAT5 antibodies for precipitation and IRL antibodies for
detection of the Western blot (1) upon transient transfection
of STAT5b in Rat1 HIR cl5 cells, (Fig. 1b, right lane) and (2)
upon immunoprecipitation of endogenous STAT5 in Kym-1
cells (Fig. 1b, left lane).
3.2. Insulin mediates STAT5b, but not STAT5a tyrosine
phosphorylation
STAT5 has been recently identi¢ed as a novel substrate of
the insulin receptor and a role in the physiological regulation
of insulin responses has been proposed [15]. Both STAT5 iso-
forms, STAT5a (94 kDa) and STAT5b (92 kDa) are expressed
in Kym-1 rhabdomyosarcoma cells, and could be distin-
guished by speci¢c antibodies. Interestingly, only STAT5b,
but not STAT5a was tyrosine phosphorylated after insulin
treatment, indicating an exclusive role of STAT5b in insulin
signalling in these cells (Fig. 2a). To demonstrate that insulin-
induced STAT5b phosphorylation is linked to the insulin re-
ceptor kinase activity, tyrosine phosphorylation of STAT5b in
presence of the insulin receptor kinase inhibitor HNMPA-
(AM)3 [26] was measured; a complete loss of STAT5b acti-
vation was noted under these conditions (Fig. 2b). STAT5b
activation by insulin occurs in a time- and dose-dependent
manner. Tyrosine phosphorylation of STAT5b is readily de-
tectable 10 min upon insulin stimulation (Fig. 2c), appears at
low insulin concentrations (Fig. 2d), and is comparable in
magnitude to IFNQ-induced STAT5b phosphorylation in the
same cells (Fig. 2c).
3.3. The activation of STAT5b by insulin is independent of
JAK2
In Kym-1 cells JAK2 could be reciprocally co-immunopre-
cipitated with IRS-1 in both, untreated and insulin-stimulated
Kym-1 cells (Fig. 3a), whereas JAK2 was not detectable in
immunoprecipitates of IRL (data not shown). A constitutive
association with the IRS-1 signalling complex suggests a po-
tential involvement of JAK2 in insulin-induced STAT5 acti-
vation. However, JAK2 kinase, which has been shown to be
an upstream activator of STAT5b in IFNQ-induced STAT5
activation [3,27] appears not to be involved in insulin-induced
STAT5b activation, which is evident from the following ex-
periments: Upon insulin treatment, JAK2 was not tyrosine
phosphorylated, in comparison to IFNQ-treated cells, which
Fig. 1. a: Tyrosine phosphorylation of IRL and IRS-1 in response
to insulin. 5U106 Kym-1 cells were stimulated with insulin (100
nM) for 5 min. Cells were lysed in lysisbu¡er, and IRL or IRS-1
were immunoprecipitated. The samples were separated on SDS^
PAGE, transferred to nitrocellulose, and stained with PY speci¢c
(4G10) or IRL/IRS-1 speci¢c antibodies. b: Co-immunoprecipitation
of IRL with STAT5b. 5U106 Rat1 HIR cl5 cells, transiently trans-
fected with STAT5b (right panel), or 5U106 Kym-1 cells (left pan-
el), were lysed in lysisbu¡er and STAT5 (C-17) was immunoprecipi-
tated. The samples were separated on SDS^PAGE, transferred to
nitrocellulose and the blot was stained with antibodies against IRL.
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served as a positive control (Fig. 3b). We further demonstrate
in JAK2 kinase assays (Fig. 3c) that JAK2 was not activated
in response to insulin, whereas it was activated in response to
IFNQ. Pre-incubation of the cells with the speci¢c JAK2 in-
hibitor tyrphostin AG490 [28] had no e¡ect on insulin-in-
duced STAT5b phosphorylation, whereas under the same
conditions it blocked IFNQ-mediated STAT5b phosphoryla-
tion. Further, the IR kinase inhibitor HNMPA-(AM)3 fully
abrogated insulin-mediated STAT5b activation (Fig. 2b). To-
gether, these results show that in Kym-1 cells STAT5b is a
direct substrate of the insulin receptor kinase and that insulin
and IFNQ mediate STAT5b activation by di¡erent mecha-
nisms.
4. Discussion
Several signalling pathways leading to STAT activation are
mediated via JAKs. IFNQ and GH receptors initiate STAT5
signalling by activation of JAK2 ([3,22,27], Fig. 3b,c), which
in turn phosphorylates and activates STAT5 [27]. Recently it
was shown that STAT5b can be activated and translocated to
the nucleus in a JAK2-independent (src kinase-dependent)
way [29], and it was reasoned that JAK2 and STAT phos-
phorylation events can be mediated by independent pathways
[30]. Since in some tissues JAK2 was described to be rapidly
activated after insulin infusion [24], and STAT5 was reported
to be activated upon re-feeding experiments in skeletal muscle
in vivo [15] as well as in myotubes in vitro [17], our aim was
to investigate the insulin-induced activation mechanism of
STAT5 in the rhabdomyosarcoma cell line Kym-1 with re-
spect to involvement of JAK2 and potential STAT isoform
selectivity. We here clearly demonstrate for this cell line, using
insulin concentrations, which do not cross-activate the IGF-1
receptor (data not shown) that JAK2 is not involved in the
insulin-induced activation of STAT5, as evident from lack of
JAK2 kinase activity in insulin-treated cells (Fig. 3b,c) and
abrogation of STAT5 phosphorylation only by an inhibitor
of IRL (Fig. 2b), but not by a JAK2 speci¢c kinase inhibitor
(Fig. 3d). Similarly, we have recently shown insulin-induced
STAT5 activation in a murine myoblast line (pmi28) upon
di¡erentiation into multinucleated myotubes [17]. In these
myotubes, like in Kym-1 cells, insulin failed to induce JAK2
kinase activity (P.S., unpublished data). In accordance with
the view of di¡erential signal pathway usage for STAT5 acti-
vation is our ¢nding with Kym-1 cells that in this cell line
IFNQ-induced STAT5 activation is JAK2-dependent (Figs.
2c,3b,d). Together, the data presented here con¢rm results
from cell-free kinase assays with STAT5 proteins, demonstrat-
ing direct phosphorylation by the insulin receptor kinase [15].
Further, our data extend these ¢ndings by de¢ning an iso-
form-selective activation, namely STAT5b. The direct interac-
tion [16], and co-immunoprecipitation of IRL and STAT5b
from intact cells (Fig. 1b) further argue for a direct activation
of STAT5 by the insulin receptor in vivo.
Fig. 2. a: STAT5b, but not STAT5a is phosphorylated after insulin treatment in Kym-1 cells. 5U106 Kym-1 cells were stimulated with insulin
(100 nM) for 10 min. Cells were lysed in lysisbu¡er and STAT5a (L-20, selective for STAT5a) or STAT5b (G-2, selective for STAT5b) were
immunoprecipitated. The samples were separated on SDS^PAGE, transferred to nitrocellulose and stained with PY (4G10), STAT5a, or
STAT5b speci¢c antibodies. b: Inhibition of STAT5b activation with HNMPA-(AM)3. 5U106 Kym-1 cells were serum starved for 2 h in pres-
ence of 10 WM HNMPA-(AM)3 and stimulated with insulin (100 nM) for 10 min. Cells were lysed in lysisbu¡er and STAT5b (G-2) was immu-
noprecipitated. The samples were separated on SDS^PAGE, transferred to nitrocellulose and stained with antibodies against PY (4G10) or
STAT5b (G-2). c,d: Time and dose dependence of insulin-induced tyrosine phosphorylation of STAT5b. 5U106 Kym-1 cells were stimulated
with insulin (10 nM) for the indicated times (50 ng/ml IFNQ served as positive control), or stimulated with indicated insulin concentrations for
10 min. Cells were lysed in lysisbu¡er and STAT5b (G-2) was immunoprecipitated. The samples were separated on SDS^PAGE, transferred to
nitrocellulose and stained with PY (4G10) or STAT5b (G-2) speci¢c antibodies.
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The JAK2 independence of insulin-induced STAT5 activa-
tion despite constitutive association of JAK2 with IRS-1 in
Kym-1 cells (Fig. 3a) is of note and illustrates the complexity
of this multifunctional signalling module. The function of
JAK2 in the IRS-1 complex is, at present, not fully under-
stood, but a role in insulin-independent phosphorylation of
IRS-1 is evident from various studies. JAK1 or JAK2 display
a di¡erent phosphorylation pattern of IRS-1 compared to the
IRL [31], and thus are likely to initiate a di¡erent spectrum of
downstream pathways [20,31^33]. For example, using JAK2
de¢cient cell lines, or expressing a dominant negative mutant
of JAK2, Yamauchi et al. showed that JAK2 is required in
GH- and PRL-dependent IRS-1 and IRS-2 tyrosine phos-
phorylation [34]. JAK2 is also implicated in cell proliferation
and the co-precipitation (Fig. 3a) with as well as the basal
phosphorylation of IRS-1 in Kym-1 cells (Fig. 1a) could re-
£ect a constitutive signalling towards mitogenic pathways or
PI 3-kinase activation [34] via autocrine acting factors pro-
duced by the tumor cells such as GH or IGFs.
Recently, distinct functional roles for both STAT5 isoforms
were described [3,35]. The phenotypes of mice with deleted
STAT5a and STAT5b genes demonstrate some redundant
but also individual functions for the two STAT proteins,
and the loss of either one cannot be compensated by the other
isoform [18,36^38]. A selective engagement of the two iso-
forms by distinct extracellular stimuli becomes increasingly
apparent. Thus, it was shown that upon GM-CSF stimulation
of blood monocytes a selective, JAK2-dependent activation of
STAT5a occurs [35]. The data presented here with Kym-1
rhabdomyosarcoma cells, showing that insulin selectively ac-
tivates, in a JAK2-independent manner, STAT5b, but not
STAT5a provides further experimental evidence for a di¡er-
ential functional role of these two closely related isoforms. In
conclusion, our data show that in myosarcoma (this study)
Fig. 3. JAK2 is co-immunoprecipitated with IRS-1, but not activated by insulin treatment. a: Co-immunoprecipitation of IRS-1 and JAK2.
15U106 Kym-1 cells were serum starved for 2 h and left untreated, or stimulated with insulin (100 nM) for 10 min. Cells were lysed in lysis-
bu¡er and IRS-1 (left panel) or JAK2 (right panel) were immunoprecipitated. The samples were separated on SDS^PAGE, transferred to nitro-
cellulose, and stained with antibodies against IRS-1 and JAK2. b: 5U106 Kym-1 cells were serum starved for 2 h and stimulated with insulin
(50 nM) or IFNQ (50 ng/ml, positive control) for 5 min. Cells were lysed in lysisbu¡er and JAK2 was immunoprecipitated. The samples were
separated on SDS^PAGE, transferred to nitrocellulose, and stained with antibodies against PY (4G10), or JAK2. c: 15U106 Kym-1 cells were
serum starved for 2 h and stimulated with insulin (100 nM, right panel) for indicated times, or IFNQ (50 ng/ml, 5 min, left panel). Cells were
lysed in lysisbu¡er and JAK2 was immunoprecipitated. A JAK2 kinase assay was performed and the samples were separated on SDS^PAGE,
transferred to nitrocellulose, and visualized by autoradiography d: STAT5b activation by insulin is independent of JAK2. 5U106 Kym-1 cells
were serum starved for 2 h in presence of tyrphostin AG490 (as indicated) and stimulated with insulin (100 nM), or IFNQ (50 ng/ml) for 5 min.
Cells were lysed in lysisbu¡er and STAT5b (G-2) was immunoprecipitated. The samples were separated on SDS^PAGE, transferred to nitro-
cellulose and stained with antibodies against PY (4G10).
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and muscle cells [17] the insulin-induced activation of
STAT5b is a direct IRL-mediated event and suggest a speci¢c
function of the STAT5b isoform in insulin-regulated gene in-
duction.
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